Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytovance to Manufacture Bexion’s First Clinical Compound | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cytovance to Manufacture Bexion’s First Clinical Compound

To manufacture the protein component and active ingredient for BXQ-350 to support Phase II trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bexion Pharmaceuticals Inc. has selected Cytovance Biologics, Inc. to manufacture the protein component and active ingredient for Bexion’s first clinical compound, BXQ-350 to support Bexion’s drug development efforts, including planned Phase II trials. 
 
BXQ-350 is a formulation of the human lysosomal protein, Saposin C, and the phospholipid dioleoylphosphatidylserine (DOPS). The companies are working on the scale-up process in anticipation of increased drug requirements.

Bexion recently completed a Phase Ia dose ranging study in patients with advanced solid tumors, where BXQ-350 was shown to be well tolerated at all five doses with no dose limiting toxicities observed and no serious adverse events. Phase Ib is now underway.
 
“As Bexion’s need for BXQ-350 has continued to increase, Cytovance has been very responsive to our requests,” said Dr. Ray Takigiku, founder and chief executive officer of Bexion. “From scheduling multiple protein runs to improving our process, their team has provided welcomed expertise.”
 
“Cytovance is very excited to be a part of such an innovative project with Bexion,” said Mike O’Mara, vice president of manufacturing at Cytovance Biologics. “We are delighted to support Bexion by ongoing manufacturing of BXQ-350 in our cGMP state-of-the-art facilities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics